Order Article Reprints

Al-Rabia MW, Alhakamy NA, Ahmed OAA, Eljaaly K, Alaofi AL, Mostafa A, Asfour HZ, Aldarmahi AA, Darwish KM, Ibrahim TS, et al. Repurposing of Sitagliptin- Melittin Optimized Nanoformula against SARS-CoV-2; Antiviral Screening and Molecular Docking Studies. Pharmaceutics. 2021; 13(3):307. https://doi.org/10.3390/pharmaceutics13030307

Al-Rabia, Mohammed W., Nabil A. Alhakamy, Osama A. A. Ahmed, Khalid Eljaaly, Ahmed L. Alaofi, Ahmed Mostafa, Hani Z. Asfour, Ahmed A. Aldarmahi, Khaled M. Darwish, Tarek S. Ibrahim, and et al. 2021. "Repurposing of Sitagliptin- Melittin Optimized Nanoformula against SARS-CoV-2; Antiviral Screening and Molecular Docking Studies" Pharmaceutics 13, no. 3: 307. https://doi.org/10.3390/pharmaceutics13030307

Al-Rabia, M. W., Alhakamy, N. A., Ahmed, O. A. A., Eljaaly, K., Alaofi, A. L., Mostafa, A., Asfour, H. Z., Aldarmahi, A. A., Darwish, K. M., Ibrahim, T. S., & Fahmy, U. A. (2021). Repurposing of Sitagliptin- Melittin Optimized Nanoformula against SARS-CoV-2; Antiviral Screening and Molecular Docking Studies. Pharmaceutics, 13(3), 307. https://doi.org/10.3390/pharmaceutics13030307